Business
In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx
Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™
About this update from Caredx, Inc.
[{"type":"text","content":"Natera Recycles Old IP for New Lawsuits\n SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents that are variations of the original patent that Natera continues to assert against CareDx. CareDx believes all the recycled patents asserted against CareDx are invalid and are not infringed. These IP filings follow a notable jury trial from March of this year that found Natera intentionally engaged in false advertising in promotion of their Prospera test. The jury unanimously awarded CareDx $44.9M in punitive and compensatory damages. The evidence at trial, including emails from the most senior levels of Natera and its CEO, showed a systematic approach to mislead transplant clinicians. “I am proud of CareDx being 100% focused on transplant for more than two decades,” said Dr. Reg Seeto, CEO and President of CareDx. “Importantly, because we have developed a transplant specific test, we ensured it covers every single somatic chromosome.” CareDx developed the first and leading donor-derived cell-free DNA technology with AlloSure for transplant patients. AlloSure was developed specifically for transplant patient care, not for prenatal or oncology testing. CareDx initiated an IP lawsuit against Natera in March 2019, and continues to believe Natera is infringing multiple CareDx patents. About CareDx – The Transplant CompanyCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. Forward Looking StatementsThis press release includes forward-looking statements related to CareDx, Inc., including state...